Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Neoplasms by Histologic Type 2Myeloproliferative Disorders 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Small Cell Lung Carcinoma 1Piebaldism 1Malignant Hepatobiliary Neoplasm 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Blast Crisis 1Adenocarcinoma of Lung 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Peripheral Blood Stem Cell Transplantation 49Mycophenolic Acid 39Busulfan 38Tacrolimus 37Cyclosporine 33Antilymphocyte Serum 33Whole-Body Irradiation 32Filgrastim 28Methotrexate 27Radiotherapy 20Melphalan 18Cytarabine 17fludarabine 16Etoposide 16Methylprednisolone 14ruxolitinib 11sargramostim 9Flow Cytometry 9Cyclosporins 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 9thymoglobulin 8Sirolimus 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Azacitidine 8merphos 7Decitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Myeloproliferative Disorders × ponatinib × Clear all
NCT02467270 2026-03-17

OPTIC

Takeda

Phase 2 Completed
283 enrolled 31 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡